Washington, DC - Luitpold Animal Health, manufacturer of Adequan® i.m., is committed to advancing the cause of better animal health through scientifically proven and FDA-approved products. “Our support of the American Horse Council continues to be paramount concerning the future of the equine industry,” stated Allyn Mann, Director at Luitpold Animal Health. “It is the only forum that brings all segments of the industry together to discuss vital issues related to the present and future of the equine industry. I would encourage any company that is involved in the equine industry to support the American Horse Council.” As part of its 2015 sponsorship of the AHC, Luitpold will be sponsoring the Council’s National Issues Forum on June 16th for the seventh year in a row. The National Issues Forum focuses on the health, welfare, and integrity of the horse and horse industry and is attended by hundreds of leaders in the horse industry.
Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc. the manufacturer of the joint therapy(polysulfated glycosaminoglycan), has continued its commitment to the horse industry by renewing its annual sponsorship for 2015 The American Horse Council (AHC).
Founded in 1969, the AHC was organized by a group of horsemen concerned about federal legislation affecting their industry. They recognized the need for national and coordinated industry action in Washington, DC. As the national association representing all segments of the horse industry in Washington, DC, the AHC works daily to represent equine interests and opportunities.
Since its inception, the AHC has been promoting and protecting the equine industry by representing its interests in Congress and in federal regulatory agencies on national issues such as taxes, health and contagious disease outbreaks, welfare issues, gaming, disaster assistance programs, immigration issues, and trail and public land use. The AHC is a non-profit organization and depends on individual membership from the horse community as well as sponsorships.
Maintaining the health and soundness of equine athletes is one of the keys to their success. Adequan® i.m. is a veterinarian-trusted name in the treatment against equine degenerative joint disease, and is the only FDA-approved intramuscular polysulfated glycosaminoglycan for use in the equine. Treatment with Adequan® i.m. has been shown to stop the destructive disease cycle, reverse non-infectious degenerative joint disease and improve joint function. If you suspect your equine athlete or companion horse is experiencing non-infectious degenerative joint disease, speak to your veterinarian and find out if Adequan® i.m., “The Winning Formula for Champions,” can benefit your horse.
Luitpold has been a strong supporter of the AHC since 2008, and has proven that it is committed in helping ensure the success and growth of the entire horse industry in the United States. “It is a real pleasure to see how committed Luitpold Pharmaceuticals is to the issues that we work on. Allyn Mann came to Capitol Hill to lobby with us during our annual meeting last year. It is great to know that we have such dedicated support,” said James Hickey, President of the AHC.
As part of its 2015 sponsorship of the AHC, Luitpold will be sponsoring the Council’s National Issues Forum on June 16th for the seventh year in a row. The National Issues Forum focuses on the health, welfare, and integrity of the horse and horse industry and is attended by hundreds of leaders in the horse industry.